Bayer Advances Cell and Gene Therapies for Parkinson’s Disease

Bayer has announced significant advancements in the fight against Parkinson’s disease (PD) with the initiation of two clinical trials for novel therapies. On September 22, 2025, Bayer confirmed that the first participant has received randomized treatment in the pivotal Phase III clinical trial, known as exPDite-2, for bemdaneprocel, an investigational cell therapy. Concurrently, participants in Europe have begun the randomized treatment phase in the Phase II clinical trial, REGENERATE-PD, for AB-1005, an investigational gene therapy.

Both therapies target individuals suffering from moderate-stage PD and are being developed in partnership with Bayer’s wholly-owned subsidiaries. BlueRock Therapeutics LP is responsible for the development of bemdaneprocel, while AskBio Inc. is overseeing the AB-1005 therapy.

Innovative Approaches to Treatment

Bayer’s progress marks a notable step in addressing the challenges posed by Parkinson’s disease, a condition that affects millions globally. The exPDite-2 trial represents a crucial stage in evaluating the effectiveness of bemdaneprocel, which aims to restore neuronal function and improve motor control in patients.

In parallel, the REGENERATE-PD trial is exploring the potential of AB-1005 to modify the underlying disease mechanisms through gene therapy. Both trials underscore Bayer’s commitment to pioneering treatments that could significantly alter the landscape of how moderate-stage PD is managed.

The exPDite-2 trial will involve a diverse group of participants, ensuring that the findings can be generalized across various demographics. By focusing on advanced therapies, Bayer is not only contributing to the scientific understanding of PD but also aiming to enhance the quality of life for those affected by this debilitating disease.

Collaborative Efforts in Research

The collaboration between Bayer and its subsidiaries illustrates a strategic approach to research and development. With the backing of experienced teams at BlueRock Therapeutics and AskBio, Bayer is leveraging innovative technology to address unmet medical needs in neurology.

As these trials progress, the medical community and patients alike will be closely monitoring outcomes. Success in either trial could pave the way for new standards in Parkinson’s disease treatment and inspire further research into other neurological disorders.

Bayer’s advancements in cell and gene therapy highlight a growing trend in the pharmaceutical industry toward personalized medicine approaches. The outcome of these trials could represent a significant leap forward in the understanding and treatment of Parkinson’s disease, offering hope to many who live with its challenges.